Clinical Trial Detail

NCT ID NCT02431559
Title A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications

fallopian tube carcinoma

ovarian carcinoma

peritoneal carcinoma

Therapies

Aldoxorubicin + Durvalumab + Motolimod

Age Groups: adult

No variant requirements are available.